Chinese Biopharmaceutical: Pembrolizumab Injection for maintenance therapy of non-small cell lung cancer after radiotherapy and chemistry has been approved for marketing.

China Biopharmaceuticals announced that the company's independently developed national category 1 innovative drug pembrolizumab has obtained approval from the China National Medical Products Administration for a new indication. It is approved for the treatment of unresectable stage III non-small cell lung cancer patients who have not shown disease progression after receiving platinum-based synchronous or sequential radiotherapy, and who do not carry known epidermal growth factor receptor sensitive mutations or anaplastic lymphoma kinase rearrangements.